Evidence map›Paper›PMID 40332380›Full record

ArticleInternational journal of molecular sciences2025

Diagnostic Potential of CD44, CD133, and VDR in Epithelial Ovarian Tumors: Association with Histopathology Parameters.

Ljubiša Jovanović, Branka Šošić-Jurjević, Anđa Ćirković, Sandra Dragičević, Branko Filipović, Svetlana Milenković, Stefan Dugalić, Miroslava Gojnić-Dugalić, Aleksandra Nikolić

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ljubiša JovanovićDepartment of Pathology and Medical Cytology, University Clinical Center of Serbia, dr Koste Todorovića 26, 11000 Belgrade, Serbia.ORCID 0000-0003-1931-4475
Branka Šošić-JurjevićDepartment of Cytology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Bulevar Despota Stefana 142, 11108 Belgrade, Serbia.ORCID 0000-0002-5496-0619
Anđa ĆirkovićInstitute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, dr Subotića 15, 11000 Belgrade, Serbia.
Sandra DragičevićLaboratory for Molecular Biology, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11000 Belgrade, Serbia.ORCID 0000-0002-1602-1880
Branko FilipovićDepartment of Cytology, Institute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, Bulevar Despota Stefana 142, 11108 Belgrade, Serbia.ORCID 0000-0001-5352-763X
Svetlana MilenkovićDepartment of Pathology and Medical Cytology, University Clinical Center of Serbia, dr Koste Todorovića 26, 11000 Belgrade, Serbia.
Stefan DugalićClinic for Gynecology and Obstetrics, University Clinical Center of Serbia, dr Koste Todorovića 26, 11000 Belgrade, Serbia.ORCID 0000-0001-5292-0595
Miroslava Gojnić-DugalićClinic for Gynecology and Obstetrics, University Clinical Center of Serbia, dr Koste Todorovića 26, 11000 Belgrade, Serbia.ORCID 0000-0002-7926-3916
Aleksandra NikolićLaboratory for Molecular Biology, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Vojvode Stepe 444a, 11000 Belgrade, Serbia.ORCID 0000-0003-3420-3896

Funding

Ministry of Science, Technology Development and Innovations of the Republic of Serbia 451-03-47/2023-01/200042 and 451-03-47/2023-01/200007
6 · The paper itself

Abstract

Cancer stem cells (CSCs) significantly contribute to heterogeneity, malignancy, and therapy resistance in ovarian cancer. Recent studies emphasize the role of the vitamin D receptor (VDR) in regulating cell differentiation and stemness in various types of cancer. This study aims to determine the expression levels of CD44, CD133, and VDR in epithelial ovarian tumors (EOTs) and to compare these levels across different tumor types, including benign, atypical proliferative tumors, and five types of malignant phenotypes, in order to evaluate their potential as diagnostic tools for malignancy. Tissue samples from 218 patients diagnosed with EOT were analyzed. Clinical and histopathologic parameters were recorded. Quantitative immunohistochemical tissue microarray analysis was used to assess the expression levels of CD44, CD133, and VDR using two different scoring systems. Comparisons were made between benign tumors (n = 45), atypical proliferative tumors (n = 42), and ovarian carcinomas (n = 131), including high-grade serous (HGSC) and non-HGSC subtypes. Ovarian cancer, especially HGSC, showed a significantly higher expression of CD44 and VDR (

Indexed as

AC133 AntigenCarcinoma, Ovarian EpithelialHyaluronan ReceptorsOvarian NeoplasmsReceptors, CalcitriolAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMiddle AgedAC133 AntigenBiomarkers, TumorCD44 protein, humanHyaluronan ReceptorsPROM1 protein, humanReceptors, CalcitriolVDR protein, humancancer stem cellsCD133CD44immunohistochemistryovarian cancervitamin D receptor

Identifiers

PMID40332380
PMCPMC12028036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.